We serve Chemical Name:4-[methyl(methylsulfonyl)amino]benzoic acid CAS:200393-68-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![4-[methyl(methylsulfonyl)amino]benzoic acid](https://a.dearchem.com/CAS2/200393-68-6.png)
Chemical Name:4-[methyl(methylsulfonyl)amino]benzoic acid
CAS.NO:200393-68-6
Synonyms:hms1724o04
Molecular Formula:C9H11NO4S
Molecular Weight:229.25300
HS Code:2935009090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:420.3ºC at 760 mmHg
Density:1.424g/cm3
Index of Refraction:1.598
PSA:83.06000
Exact Mass:229.04100
LogP:1.86140
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like hms1724o04 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,hms1724o04 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,hms1724o04 Use and application,hms1724o04 technical grade,usp/ep/jp grade.
Related News: Events, Hatzalah of South Florida, and Ygrene and in partnership with the Shul of Bal Harbour we are able to continue this mission by providing first and last month rent as well as the security deposit for these families If this fund grows bigger, we will be able to continue to contribute funds directly for the rents.” Michael Capponi
“During this challenging time for the survivors, the uncertainty of not knowing where they will live exacerbates an already extremely painful and tragic situation. We are committed to the relocation efforts of all of the survivors through our partnership with Global Empowerment Mission.” Rabbi Zalman Lipskar, The Shul of Bal Harbour.
“We are devastated by the loss suffered by the victims, families of victims and the community at the hands of the Surfside tragedy. It is an honor to contribute to GEM’s Champlain Survivor Relocation Fund to provide safe and comfortable homes for survivors to help them get back on their feet, ” said Ygrene CEO, Jim Reinhart.
Baclofen is a muscle relaxant drug indicated for the treatment of muscle pain, spasms, and stiffness in people with multiple sclerosis, spinal cord injury, or disease.
This is Beximco Pharma’s ninth Abbreviated New Drug Application fully developed in-house and successfully approved for the US market since the Company’s oral solid dosage facility was approved by the US FDA in June 2015.
According to IQVIA audited market data, there are currently nine active players for Baclofen in the US market, which generated sales of more than $110 million in 2020.
Mr. Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals, said: We are pleased to have received FDA approval of Baclofen, a commonly prescribed medicine in the US, as we continue to leverage our core strengths in R&D and manufacturing to develop and deliver important generic products to patients. (1R)-N-diphenylphosphoryl-1-naphthalen-1-ylpropan-1-amine manufacturers Joan Merrill, Oklahoma Medical Research Foundation, Arthritis & Clinical Immunology Research Program, US, said: “Arthritis and rash are the most common and persistent problems in lupus and often have a significant impact on a person’s life. The strength of the data from this analysis is that anifrolumab was found to be consistently effective using three different ways of looking at rash and three different approaches to arthritis. methyltrioxorhenium suppliers Expedite biocatalysis development by partnering with an API CDMO AC-3,5-DINITRO-TYR-OET vendor & factory.
“During this challenging time for the survivors, the uncertainty of not knowing where they will live exacerbates an already extremely painful and tragic situation. We are committed to the relocation efforts of all of the survivors through our partnership with Global Empowerment Mission.” Rabbi Zalman Lipskar, The Shul of Bal Harbour.
“We are devastated by the loss suffered by the victims, families of victims and the community at the hands of the Surfside tragedy. It is an honor to contribute to GEM’s Champlain Survivor Relocation Fund to provide safe and comfortable homes for survivors to help them get back on their feet, ” said Ygrene CEO, Jim Reinhart.
Baclofen is a muscle relaxant drug indicated for the treatment of muscle pain, spasms, and stiffness in people with multiple sclerosis, spinal cord injury, or disease.
This is Beximco Pharma’s ninth Abbreviated New Drug Application fully developed in-house and successfully approved for the US market since the Company’s oral solid dosage facility was approved by the US FDA in June 2015.
According to IQVIA audited market data, there are currently nine active players for Baclofen in the US market, which generated sales of more than $110 million in 2020.
Mr. Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals, said: We are pleased to have received FDA approval of Baclofen, a commonly prescribed medicine in the US, as we continue to leverage our core strengths in R&D and manufacturing to develop and deliver important generic products to patients. (1R)-N-diphenylphosphoryl-1-naphthalen-1-ylpropan-1-amine manufacturers Joan Merrill, Oklahoma Medical Research Foundation, Arthritis & Clinical Immunology Research Program, US, said: “Arthritis and rash are the most common and persistent problems in lupus and often have a significant impact on a person’s life. The strength of the data from this analysis is that anifrolumab was found to be consistently effective using three different ways of looking at rash and three different approaches to arthritis. methyltrioxorhenium suppliers Expedite biocatalysis development by partnering with an API CDMO AC-3,5-DINITRO-TYR-OET vendor & factory.
